Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven - MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company ...
Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven – MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NPCE), a medical device company focused on ...
EQT is pleased to announce that EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics ("Atalanta" or "the Company"). Atalanta, a biotechnology company based in ...